GC Cell Corporation (144510:KOSDAQ), fully integrated company involved in cell and gene therapy and a subsidiary of Korean-listed pharmaceutical group GC Biopharma Corp, announced on Sunday that it entered into an international strategic cooperation agreement with Lukas Biomedical Co., Ltd (TWSE 6814), a Taiwan-based biomedical company, specialising in immune cell cultures.

The partnership is aimed at raising awareness of autologous T cell therapy and to expand the patient access market by using each other's strengths in innovative cell treatment areas. Both companies aim to accelerate drug development and establish a platform for precision medicine solutions by sharing research projects, clinical trial data, regulatory knowledge across multiple countries, and exploring clinical research, market development and various activities for cancers and other challenging diseases. The collaboration aims to bring the benefits of innovative cell therapy to a wider range of patients.

James Park, GC Cell CEO, said, 'This strategic cooperation agreement represents a pivotal milestone in accelerating the advancement of innovative cell therapies in Korea and Taiwan and also in establishing global network and ecosystem of Cell and Gene Therapy. Looking ahead, we are committed to accelerating the global expansion of Immuncell-LC through the continuous exchange of clinical research data and the establishment of a strong, long-term partnership between our two companies.'